REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,

Slides:



Advertisements
Similar presentations
The United States Federal Food, Drug, and Cosmetic Act (FFDCA)
Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Food Science: An Old but New Subject History of Food Science
Steven D. Vaughn, DVM Director Office of New Animal Drug Evaluation Center for Veterinary Medicine U. S. Food and Drug Administration June 6, 2012 Embracing.
Prof. A. De Wever SAFETY, EFFICACY, QUALITY AND RISK/BENFIT RATIO Source : Marc Czarka.
Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
History of FDA and Related Regulatory Agencies
Government Agencies HUM-FNW-3 Unit 4. USDA United States Department of Agriculture Mission Statement We provide leadership on food, agriculture, natural.
Regulation and Safety Assessment of Novel Foods in Canada William Yan, Ph.D. Office of Food Biotechnology Health Canada.
Introduction to Regulation
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
"Informational needs and the regulatory frame for consumer applications: The EU Commission's view" Philippe Martin European Commission Directorate-General.
What Do Toxicologists Do?
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Herbal Products Presented by Janice Hermann, PhD, RD/LD
ACPS October Nanotechnology: Issues and Future Directions Nakissa Sadrieh Ph.D. OPS/CDER/FDA.
Ohio Nano-Summit March 3, 2005 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D. Associate.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
-Drafted in Amendment Years were in 1954 and National law in United States.
The Changing Food Environment The Role and Activities of the U.S. Food and Drug Administration Transatlantic Consumer Dialogue The Changing Food Environment.
1 The Bioterrorism Act and Food 2217 Steven C Seideman Extension Food Processing Specialist Cooperative Extension Service University of Arkansas.
FDA Considerations For Regulation Of Nanomaterial Containing Products
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Cellular Products for Cardiac Diseases Dwaine Rieves, MD Center for Biologics Evaluation and Research FDA Perspective on:
1 FDA Perspective on Nanomaterial- Containing Products Nakissa Sadrieh, Ph.D. Office of Pharmaceutical Science Center for Drug Evaluation and Research.
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
FDA, PDUFA AND MEDICAL INNOVATION Spring WHAT IS THE FOOD AND DRUG ADMINISTRATION (FDA)? The FDA is an agency within the U.S. Department of Health.
Images shutterstock.com Food Science: An Old but New Subject Chapter 1 Remind Ms J to clock in.
1 Update on Nanotechnology Activities in CDER and FDA Keith O. Webber, Ph.D. Deputy Director OPS/CDER/FDA ACPS Meeting Tuesday, July 22, 2008.
Regulation and Labeling Food Technology Ch 26. Regulation and Labeling The Food and Drug Administration (FDA) and the United States Dept of Agriculture.
3/3/2010Handshake to Success Crescent Healthcare is a premier infusion company founded in 1992 to provide home infusion services to patients with chronic.
Center for Food Safety and Applied Nutrition (CFSAN) Golriz Khadem And Ryan Leitz.
Food and Drug Administration & Outbreaks
1 FDA Perspective on Nanomaterial- Containing Products Nakissa Sadrieh, Ph.D. Associate Director for Research Policy and Implementation Office of Pharmaceutical.
1 Risk Governance of Manufactured Nanoparticles, Joint Workshop EP STOA Panel – European Commission, Brussels, 21 November 2011 Interfaces between Science.
1 CDRH: Minimizing Risk of TSE Agents in Medical Devices CDR Martha O’Lone, RN, BSN CDRH TSE Working Group Chair Infection Control Devices Branch DAGID.
TSE Advisory Committee October 25, 2001 Center for Food Safety and Applied Nutrition Food and Drug Administration Washington, DC Topic 3.
Public Health and Risk Assessment (2nd of 10 Lectures on Toxicologic Epidemiology) Michael H. Dong MPH, DrPA, PhD  readings.
Utah Life Science Summit Nov Phil Triolo, PhD RAC President, Phil Triolo and Associates LC.
Component 1: Introduction to Health Care and Public Health in the U.S. 1.1: Unit 2: Health Care Settings 1.2 a: Overview and the Organization of Federal.
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
 Food and Drug Administration The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
2 Objectives 1.To identify and distinguish among government agencies and their role in food safety 2.To analyze and apply the laws set by government agencies.
Nano means: o Prefix that means “one-billionth” o 10⁻⁹ o For example: nanometer (nm) is one-billionth of a meter o Red blood cell is about 6,000-10,000.
Introduction to the Canadian Food Safety System Roles and Responsibilities in Food Surveillance December 9, 2013 Samuel Godefroy, Ph.D. Director General,
Executive Director, Registrar Corp
Quality Management.
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
Case Studies in Big Data and Analysis
Clinical Trials — A Closer Look
Food and drug administration
Government Regulations to Control Diseases
American Society for Quality Region 5 Quality Conference
Overview of FDA Food Inspections
Beyond Academia.
Government Regulations for Disease Prevention
Patient Involvement in the Development and Safe Use of
FDA Regulated Special Interest Group
Final Rule on Foreign Supplier Verification Programs
Nanotechnology: Issues and Future Directions
Presentation transcript:

REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson, PhD Associate Commissioner for Science Food and Drug Administration

Briefly Today FDA mission FDA regulated products Nano and FDA products Benefits of nanomaterials Regulation of nano products Nano challenges, concerns, and research need What products are we seeing?

33 FDA Mission The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health.

FDA Regulated Products Foods –All interstate domestic and imported, including produce, fish, shellfish, shell eggs, milk (not meat or poultry) –Bottled water –Wine (<7 alcohol) –Infant formula Food additives –Colors –Food containers4444 Cosmetics Dietary Supplements Animal Feeds Pharmaceuticals –Human –Animal –Tamper resistant packaging Medical devices Radiation emitting electronic products Vaccines Blood products Tissues Sterilants Counter-terrorism products

FDA’s Core Business Functions Pre-Market Review Product Safety & Compliance Consumer & Patient Safety Assessment of safety and effectiveness of new medical technology & safety of new food ingredients Inspection of manufacturing facilities and products to assure safety, quality & compliance with FDA regulations Post-marketing surveillance to ensure the safety of consumers & patients who use FDA- regulated products

Nanoscale Materials and FDA - Products Drugs (NMEs, new formulations, Imaging agents) Medical devices (in contact/not in contact with human body ) Tissue engineering, biological products (blood substitutes, virus-like particle vaccines) Nutritional supplements/food additives Cosmetics Combination products

Public Health Benefits New treatments – not possible before –Solubility/absorption changes ‘bringing back” development candidates –Totally new concepts possible – limited only by the science Lower toxicity – targeted delivery –Increase drug concentration at needed site –Decrease systemic exposure to drug Combinations of therapies Serve as scaffolding to attach chemical moieties

Cost Benefits Extend lifespan of products by reformulating through novel delivery systems Enhance effective patent protection Cost differential between delivery formulation vs. drug discovery for NME Minimizing use of expensive drugs to reduce cost of product

FDA NANOTECHNOLOGY TASK FORCE REPORT Nanoscale materials could be used in most product types regulated by FDA Regulation driven by statutory classification rather than technology Range of regulatory authority Review products, not technology Nanoscale materials present challenges similar to other emerging technologies Size can affect biological interaction—BUT NOT ALWAYS Review challenges – safety, efficacy, metrology, characterization, industrialization Steps should be taken to better inform FDA reviewers and industry about what is known, needed, and expected. No new regulations needed at this time.

REGULATORY POLICY RECOMMENDATIONS Labeling – Case-by-case decision driven by safety considerations, no false or misleading information Guidance to industry – currently reviewing existing guidances to determine whether adequate of identification of nano-particles. National Environmental Policy Act – Case-by- case, determine whether a nanoscale product qualifies for exemption

Challenges of Nano-Engineered Materials Lack of standards and reference materials Determining bioavailability/biodistribution Lack of toxicological and biocompatibility data Bridging preclinical– clinical gaps Lack of standardized physical and chemical characterization procedures Manufacturing scale-up

GUIDANCE REVIEW Food and color additives Nutritional supplements Pharmaceuticals Medical devices – 510(k) Cosmetics

Nanoscale Materials in FDA Products Drugs –Antineoplastic –Antifungal –Anesthetic Food ingredients Sunscreen materials Devices –Dental filling –Bone filler –Catheter Drug delivery materials MRI contrasting agents Food and beverage containers Implant materials

With Basic Data on Nano- Materials FDA can –Ask the right questions –Reduce risk of nanomaterials –Speed products to consumer –Reduce cost Improve public health

THANK YOU